Exploring Dopamine-Modified Hyaluronic Acid as a Potential Parkinson’s Disease Treatment

Parkinson’s disease (PD) is a disorder that affects over 8.5 million individuals worldwide. PD is caused by the death of dopamine (DA) cells, a neurotransmitter that plays a vital role in various bodily functions. The decrease of DA leads to many symptoms such as tremors. Many speculate that oxidative stress is the major trigger of the DA decrease. The current treatment of PD, levodopa, increases DA concentration and reduces PD symptoms. However, levodopa is attributed to inducing oxidative stress in the long term, which can cause further damage. Therefore, discovering a substance that can treat PD without causing oxidative stress is crucial. We are proposing a new substance, DA-HA, that could effectively treat PD without inducing oxidative stress.